Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02213042
Title Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

Her2-receptor positive breast cancer


Lapatinib + Trastuzumab


Age Groups: adult | senior
Covered Countries USA | ITA | ESP | AUT

No variant requirements are available.